2. Search Result
Search Result
Isoforms Recommended: SGLT1
Results for "

SGLT1

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

5

Natural
Products

2

Recombinant Proteins

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-123797
    KGA-2727
    1 Publications Verification

    		 SGLT Metabolic Disease
    KGA-2727 is a first selective, high-affinity and orally active SGLT1 inhibitor with Kis of 97.4 nM and 43.5 nM for human and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 has antidiabetic efficacy [1].
    KGA-2727
  • HY-14894
    Ipragliflozin
    5+ Cited Publications

    ASP1941

    		 SGLT Metabolic Disease
    Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC50s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent [1].
    Ipragliflozin
  • HY-109092
    Licogliflozin
    1 Publications Verification

    LIK066

    		 SGLT Metabolic Disease Inflammation/Immunology
    Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor.
    Licogliflozin
  • HY-138944
    SGLT1/2-IN-1

    		SGLT Metabolic Disease
    SGLT1/2-IN-1 is a dual SGLT1/SGLT2 inhibitor extract from WO2015032272A1, compound 2 [1].
    SGLT1/2-IN-1
  • HY-145357
    SGLT1/2-IN-2

    		SGLT Metabolic Disease
    SGLT1/2-IN-2 demonstrates potent dual inhibitory activities (IC50 = 96 nM for SGLT1 and IC50 = 1.3 nM for SGLT2).
    SGLT1/2-IN-2
  • HY-169821
    SGLT1/2-IN-8

    		SGLT Metabolic Disease
    SGLT1/2-IN-8 (compound 8) is a potent and orally active SGLT1/2 dual inhibitor with IC50 values of 4 nM and 1 nM, respectively. SGLT1/2-IN-8 exhibits anti-hyperglycemic effects and can be utilized in relevant research [1].
    SGLT1/2-IN-8
  • HY-124664
    TP0438836

    		SGLT Metabolic Disease
    TP0438836 (compound 30b) is a SGLT1 inhibitor, with IC50 values ​​of 28 nM and 7 nM for hSGLT1 and hSGLT2, respectively. TP0438836 can be used in diabetes research [1].
    TP0438836
  • HY-123011
    Henagliflozin

    SHR3824

    		 SGLT Metabolic Disease
    Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC50 values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research [1].
    Henagliflozin
  • HY-106158
    T-1095

    		SGLT Metabolic Disease
    T-1095 is a selective and orally active Na +-glucose cotransporter (SGLT) inhibitor with IC50s of 22.8 µM and 2.3 µM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research [1].
    T-1095
  • HY-14894R
    Ipragliflozin (Standard)

    		SGLT Metabolic Disease
    Ipragliflozin (Standard) is the analytical standard of Ipragliflozin. This product is intended for research and analytical applications. Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC50s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent [1].
    Ipragliflozin (Standard)
  • HY-14894S2
    Pragliflozin-13C6

    ASP1941-13C6

    		 Isotope-Labeled Compounds SGLT Metabolic Disease
    Pragliflozin- 13C6 (ASP1941- 13C6) is 13C labeled Ipragliflozin. Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC50s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent [1] .
    Pragliflozin-13C6
  • HY-101122
    LX2761

    		SGLT Metabolic Disease
    LX2761 is chemically stable and potent inhibitor against sodium-dependent glucose cotransporter 1 (SGLT1) and SGLT2 in vitro with IC50s of 2.2 nM and 2.7nM for hSGLT1 and hSGLT2, but displays specific SGLT1 inhibition in the gastrointestinal (GI) tract [1].
    LX2761
  • HY-17638
    Mizagliflozin
    3 Publications Verification

    DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base

    		 SGLT Metabolic Disease
    Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation [1].
    Mizagliflozin
  • HY-117010
    Kushenol K

    		Cytochrome P450 HSV SGLT Infection Metabolic Disease
    Kushenol K, a flavonoid antioxidant isolated from the roots of Sophora flavescens. Kushenol K is a cytochrome P-450 3A4 (CYP3A4) inhibitor with a Ki value of 1.35 μM [1]. Kushenol K shows weak antiviral activity against HSV-2 (EC50 of 147 μM) . Kushenol K also inhibits the activity of SGLT1 and SGLT2 .
    Kushenol K
  • HY-109092A
    rel-Licogliflozin

    rel-LIK066

    		 SGLT Metabolic Disease Inflammation/Immunology
    rel-Licogliflozin is a relative configuration of Licogliflozin (HY-109092). Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor [1].
    rel-Licogliflozin
  • HY-14894A
    Ipragliflozin L-Proline
    5+ Cited Publications

    		 SGLT Metabolic Disease
    Ipragliflozin (L-Proline) is a highly potent and selective SGLT2 inhibitor with an IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.
    Ipragliflozin L-Proline
  • HY-122473
    fluoro-Dapagliflozin

    		SGLT Metabolic Disease
    fluoro-Dapagliflozin, a structural analog of Dapagliflozin, is a selective SGLT2 inhibitor with Ki values of 5.3 nM and 330 nM for SGLT2 and SGLT1, respectively. fluoro-Dapagliflozin blocks glucose transport and glucose-coupled currents [1].
    fluoro-Dapagliflozin
  • HY-114308
    SGL5213

    		SGLT Metabolic Disease
    SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC50 values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. SGL5213 has potential to treat type 2 diabetes treatment [1].
    SGL5213
  • HY-10449
    Luseogliflozin

    TS 071

    		 SGLT Metabolic Disease
    Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM). Luseogliflozin has the protential for researching type 2 diabetes [1] .
    Luseogliflozin
  • HY-N4100
    Trilobatin
    2 Publications Verification

    		 TNF Receptor HIV SGLT Infection
    Trilobatin, a natural sweetener derived from Lithocarpus polystachyus Rehd [1], Trilobatin is an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope . Neuroprotective effects [1]. Trilobatin is also a SGLT1/2 inhibitor that selectively induces the proliferation of human hepatoblastoma cells .
    Trilobatin
  • HY-N4100R
    Trilobatin (Standard)

    		TNF Receptor HIV SGLT Infection
    Trilobatin (Standard) is the analytical standard of Trilobatin. This product is intended for research and analytical applications. Trilobatin, a natural sweetener derived from?Lithocarpus polystachyus?Rehd [1], Trilobatin?is an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope . Neuroprotective effects [1]. Trilobatin is also a SGLT1/2 inhibitor that selectively induces the proliferation of human hepatoblastoma cells .
    Trilobatin (Standard)
  • HY-N0142
    Phloretin
    Maximum Cited Publications
    16 Publications Verification

    NSC 407292; RJC 02792

    		 SGLT Endogenous Metabolite GLUT Metabolic Disease Cancer
    Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill.，has anti-inflammatory activities. Phloridzin is a specific，competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC50values of 49 μM and 61 μM，respectively [1].Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation .
    Phloretin
  • HY-17638A
    Mizagliflozin (sebacate)

    DSP-3235 (sebacate); KGA-3235 (sebacate); GSK-1614235 (sebacate)

    		 SGLT Neurological Disease
    Mizagliflozin sebacate (DSP-3235 sebacate) is a sodium-glucose cotransporter inhibitor with activity in improving vascular cognitive impairment caused by small vessel disease. Mizagliflozin sebacate improves blood flow and reverses vascular cognitive impairment by inhibiting neuronal SGLT1 activity. Mizagliflozin sebacate also showed the ability to increase the survival rate of IL-1β-treated PC12HS cells. Mizagliflozin sebacate promotes improvements in spatial learning and memory caused by small vessel disease in mouse models [1].
    Mizagliflozin (sebacate)
  • HY-N0142R
    Phloretin (Standard)

    NSC 407292 (Standard); RJC 02792 (Standard)

    		 SGLT Endogenous Metabolite GLUT Metabolic Disease Cancer
    Phloretin (Standard) is the analytical standard of Phloretin. This product is intended for research and analytical applications. Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC50values of 49 μM and 61 μM, respectively [1].Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation .
    Phloretin (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: